VIP (Vasoactive Intestinal Polypeptide)

Vasoactive Intestinal Peptide · Neuropeptide

Overview

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.

VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.

VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.

Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses.

Coronary vasodilation with positive inotropic and chronotropic effects on the heart.

Promising therapeutic target for Alzheimer's, Parkinson's, and other neurological disorders.

Mechanism

VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.

Research areas

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.
VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.
VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.
Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses.
Coronary vasodilation with positive inotropic and chronotropic effects on the heart.
Promising therapeutic target for Alzheimer's, Parkinson's, and other neurological disorders.
Potential therapeutic target being researched for ASD.
Produced in suprachiasmatic nuclei; involved in circadian regulation.
Promotes insulin secretion in glucose-dependent manner via VPAC2; low hypoglycemia risk.
Potent anti-inflammatory effects useful in IBD and autoimmune conditions.
Therapeutic potential for pulmonary and systemic sarcoidosis.
VIP's extremely short 1-2 minute half-life makes it impractical for routine clinical use - requiring constant infusions or multiple daily injections. Stabilized analogs (like stearyl-Nle17-VIP) are 100-fold more potent but rarely available outside research settings. Limited commercial development has restricted clinical availability despite strong research foundation.

Research notes

Vasodilation (flushing, warmth)
Hypotension
Increased heart rate
Gastrointestinal effects (diarrhea possible)
Headache
Severe hypotension
Allergic reaction symptoms
Severe diarrhea
Cardiac arrhythmias
VIPoma or related tumors
Pregnancy or breastfeeding
Severe cardiac conditions
VIP inhalation showed striking efficacy with increased mixed venous oxygen saturation and exercise capacity in pulmonary hypertension patients. However, it's complementary to conventional therapy rather than a replacement - the very short 2-minute half-life requires frequent dosing, making it challenging for long-term use without newer stabilized analogs.

Pharmacokinetics

VIP's extremely short 1-2 minute half-life makes it impractical for routine clinical use - requiring constant infusions or multiple daily injections. Stabilized analogs (like stearyl-Nle17-VIP) are 100-fold more potent but rarely available outside research settings. Limited commercial development has restricted clinical availability despite strong research foundation.

FAQs

Does VIP cause dangerous hypotension or can it be used safely in most patients?

VIP's vasodilation can cause hypotension and flushing, especially at higher doses. Careful dose titration and patient monitoring are essential. Patients with baseline hypotension or severe cardiac conditions should avoid use, but mild transient vasodilation is manageable in most populations with proper medical supervision.

Can VIP improve insulin secretion for diabetes without causing hypoglycemia?

Yes, VIP promotes glucose-dependent insulin secretion via VPAC2 receptors, meaning it only stimulates insulin when blood glucose is elevated. This glucose-dependent mechanism makes hypoglycemia risk very low compared to other insulin secretagogues, making VIP theoretically safer for diabetes support.